Abstract 111P
Background
Advanced stage colorectal cancer therapy shows positive progress by increasing overall survival (OS). Mainstay treatment still uses cytotoxic agents and oxaliplatin which results in an average survival of 18 months when combined with 5-Fluorouracil (5-FU) or capecitabine. This study aims to determine the effectiveness and safety of the use of FOLFOX and XELOX chemotherapy in advanced stage colorectal cancer patients using a meta-analysis study.
Methods
This is a meta-analysis study comparing only the Randomized Controlled Trial (RCT) study using FOLFOX and XELOX chemotherapy in patients with metastatic colorectal cancer taken from PubMed, EMBASE and The Cochrane Library using keywords: Capecitabine, FOLFOX, XELOX and metastatic colorectal.
Results
9 journals were included in the inclusion criteria and were followed by a meta-analysis study. A total of 5,873 patients were obtained with the number of groups given FOLFOX of 3,034 and 2,839 in the group given XELOX. The analysis doesn’t show evidence of publication bias in the forest plot. The results of the analysis of Progress Free Survival (PFS) found no significant heterogeneity (OR = 1.09, 95% CI: 0.97-1.23, p = 0.14), the Overall Survival (OS) analysis also did not obtain heterogeneity (OR = 0.98, 95% CI : 0.87-1.10, p = 0.77). Overall Response Rate (ORR) there were no significant differences in the two groups. All studies gave grade 3 and 4 toxicity. The results of the combined analysis showed thrombocytopenia, Hand Foot Syndrome (HFS) and diarrhea in the XELOX group were significantly higher.
Conclusions
The effectiveness of XELOX and FOLFOX found no significant differences. However, the safety of the XELOX group showed significantly more side effects. Keywords: FOLFOX, XELOX, Advanced Stage Colorectal Cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session